Study of bone cell changes in steroid-related femoral head necrosis using discarded tissue from routine hip replacement surgery

Case-control study of osteoblastic mitochondrial quality control disorder in glucocorticoid-induced osteonecrosis of the femoral head

Registry ID
ISRCTN72490358
Source registry
ISRCTN
Status
Recruiting
Study type
OBSERVATIONAL
Sponsor
Luoyang Orthopedic-Traumatological Hospital of Henan Province
Enrollment
12
Start date
2026-03-01
Completion date
2026-12-31
Last update
2026-08-17

Conditions

Summary

Glucocorticoid-induced osteonecrosis of femoral head

Detailed description

This is a non-interventional case-control study with a 1:1 matching design. The case group consists of patients diagnosed with glucocorticoid-induced osteonecrosis of femoral head (GONFH) who require total hip arthroplasty, and the control group consists of patients with femoral neck fracture who require total hip arthroplasty and are matched with the case group by age (±5 years) and the same gender. No additional interventions are provided except routine clinical treatment for all participants. During the study, relevant samples are collected after total hip arthroplasty, and tests including Western Blot, qRT-PCR, transmission electron microscopy (TEM), immunohistochemistry (IHC), HE staining and Masson staining are performed to detect the expression levels of key molecules in the PINK1/Parkin signaling pathway, mitochondrial morphology and cristae structure, and the degree of osteoblast mitochondrial quality control disorder. Statistical analysis is used to explore the correlation between mitochondrial quality control disorder and GONFH Ficat stage.

Interventions

Inclusion criteria

1. Patients diagnosed with glucocorticoid-induced osteonecrosis of femoral head (GONFH) or femoral neck fracture, who need total hip arthroplasty 2. Aged 18-70 years old 3. Femoral neck fracture patients are matched 1:1 with GONFH patients by age (±5 years) and same gender 4. The interval between injury and total hip arthroplasty is less than 3 weeks for femoral neck fracture patients 5. GONFH patients meet Ficat stage II-IV 6. Voluntarily participate and sign the informed consent form

Exclusion criteria

1. Complicated with other metabolic bone diseases, such as severe osteoporosis, hyperparathyroidism 2. Complicated with other diseases that may cause abnormal bone metabolism, such as severe diabetes, gout 3. Complicated with malignant tumors

Locations

Related clinical trials

View on source registry